Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of "Buy" from Analysts
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the […]
United States Ceoj Scott Wolchko John Mendlein Dowling Yahnke Fate Therapeutics Inc First Republic Investment Management Inc
Source: etfdailynews.com